Evaxion Expands R&D Pipeline with New AI-Designed Precision Cancer Vaccine Candidate
Evaxion A/S, a clinical-stage TechBio company, has expanded its R&D pipeline with the addition of EVX-04, an AI-designed precision cancer vaccine candidate.
EVX-04 is currently in preclinical development and will be pursued as a therapeutic vaccine against acute myeloid leukemia (AML).
Targeting Non-Conventional ERV Tumor Antigens
EVX-04 is designed to target non-conventional ERV (endogenous retrovirus) tumor antigens from the dark genome, which are present in tumors but absent in normal tissue.
- These antigens are highly attractive targets for cancer vaccines.
- Evaxion's proprietary AI-Immunology™ platform has identified ERV antigens in patient tumor sequencing data.
Evaxion has identified ERV antigens in patient tumor sequencing data using its proprietary AI-Immunology platform.
Author's summary: Evaxion expands pipeline with AI-designed cancer vaccine candidate.
More News
- Voters head to the polls for the 2025 municipal elections
- Will Prop 50 prompt a Pelosi exit? California waits on pins and needles
- Cycling Eurovelo 3, from Northern France to Belgium
- Chargers Survive Joe Alt Injury and Pick-Six to Beat Titans - LAmag
- 7 Open World RPGs With User Reviews Better Than Skyrim
- Chiefs of staff reveal life with world's most powerful
- Kimberly-Clark acquires Kenvue in $48.7 billion deal
- Inside Nike and LA Rams’ “In The Field”
- Grateful Dead vocalist Donna Jean Godchaux-MacKay dies at 78 | Fingerlakes1.com